Laboratory records do not include complete data derived from all tests, examinations and assay necessary to assure compliance with established specifications and standards.
Inspection Record
Aurobindo Pharma Ltd. Telangana — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.
Drug product expiration dates are not related to the storage conditions stated on the labeling, as determined by stability studies.
Written records of investigation of a drug complaint do not include the findings of the investigation and the follow-up.
A sample which is representative of each lot in each shipment of each active ingredient is not appropriately identified and retained.
Backup data is not assured as secure from alteration, erasure or loss through keeping hard copy or alternate systems.
Written procedures are not followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.
Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
About this record
Extracted automatically from the document US FDA published on 2019-06-10. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
